Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer by Barth, Rolf F et al.
 
Current status of boron neutron capture therapy of high grade
gliomas and recurrent head and neck cancer
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Barth, Rolf F, M Graca H Vicente, Otto K Harling, WS Kiger,
Kent J Riley, Peter J Binns, Franz M Wagner, et al. 2012.
Current status of boron neutron capture therapy of high grade
gliomas and recurrent head and neck cancer. Radiation
Oncology (London, England) 7: 146.
Published Version doi:10.1186/1748-717X-7-146
Accessed February 19, 2015 11:59:18 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10594304
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAREVIEW Open Access
Current status of boron neutron capture therapy
of high grade gliomas and recurrent head and
neck cancer
Rolf F Barth
1*, M Graca H Vicente
2, Otto K Harling
3, W S Kiger III
4, Kent J Riley
5, Peter J Binns
6, Franz M Wagner
7,
Minoru Suzuki
8, Teruhito Aihara
9, Itsuro Kato
10 and Shinji Kawabata
11
Abstract
Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and
fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is
irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling
lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent
cancers of the head and neck region and either primary or metastatic melanoma. Neutron sources for BNCT
currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural
disaster, were available in Japan, the United States, Finland and several other European countries, Argentina and
Taiwan. Accelerators producing epithermal neutron beams also could be used for BNCT and these are being
developed in several countries. It is anticipated that the first Japanese accelerator will be available for therapeutic
use in 2013. The major hurdle for the design and synthesis of boron delivery agents has been the requirement for
selective tumor targeting to achieve boron concentrations in the range of 20 μg/g. This would be sufficient to
deliver therapeutic doses of radiation with minimal normal tissue toxicity. Two boron drugs have been used
clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or “BPA”, and sodium
borocaptate or “BSH” (Na2B12H11SH). In this report we will provide an overview of other boron delivery agents that
currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry,
treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and
recurrent tumors of the head and neck region. Promising results have been obtained with both groups of patients
but these outcomes must be more rigorously evaluated in larger, possibly randomized clinical trials. Finally, we will
summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical
modality for the treatment of those malignancies for which there currently are no good treatment options.
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Introduction
Boron neutron capture therapy (BNCT) is based on the
nuclear capture and fission reactions that occur when
boron-10, which is a non-radioactive constituent of nat-
ural elemental boron, is irradiated with low energy
(0.025 eV) thermal neutrons. This results in the pro-
duction of high linear energy transfer (LET) alpha
particles (
4He) and recoiling lithium-7 (
7Li) nuclei, as
shown below.
In order to be successful, a sufficient amount of
10B
must be selectively delivered to all tumor cells (~ 20 μg/g
weight or ~10
9 atoms/cell), and enough thermal neutrons
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10B
(n,α)
7Li capture reaction [1]. The destructive effects of
these high energy particles are limited to boron containing
cells and since they have very short pathlengths in tissues
(5–9 μm), in theory BNCT provides a way to selectively
destroy malignant cells and spare adjacent normal cells.
Clinical interest in BNCT has focused primarily on high
grade gliomas [1-3], and more recently on patients with
recurrent tumors of the head and neck region [4-7] who
have failed conventional therapy. BNCT primarily is a bio-
chemically rather than a physically targeted type of radi-
ation therapy, and, therefore, it should be possible to
selectively destroy tumor cells dispersed in normal tissue,
providing that sufficient amounts of
10Ba n dt h e r m a l
neutrons are delivered to the site of the tumor. In
this report, we will provide an update on BNCT, as it
relates to the treatment of high grade gliomas and
cancers of the head and neck region. We will briefly
summarize current developments in the design and syn-
thesis boron delivery agents, neutron sources, clinical dos-
imetry, treatment planning techniques, and past and
ongoing clinical trials in the United States, Japan and
Europe and finally, critical issues that must be addressed if
BNCT is to be successful. Readers interested in more in-
depth coverage of these and other topics related to BNCT
are referred to the Proceedings of 13
th and 14
th Inter-
national Congresses on Neutron Capture Therapy [8,9].
Boron delivery agents
General requirements
Research in the area of development of boron-containing
delivery agents for BNCTstarted~50 years ago with the in-
vestigation of a large number of low molecular weight
boron compounds, from which the first generation agents
emerged. The most important requirements for a BNCT
delivery agent are: 1.) low toxicity and normal tissue uptake,
with a tumor:normal tissue and tumor:blood (T:Bl) boron
concentration ratios of ~3; 2.) tumor boron concentration
of ~20 μg
10B/g tumor; 3.) relatively rapid clearance from
blood and normal tissues, and persistence in tumor during
neutron irradiations. The only two BNCT delivery agents
currently used in clinical trials are sodium mercaptounde-
cahydro-closo-dodecaborate (Na2B12H11SH), commonly
known as sodium borocaptate (BSH), and the boron-
containing amino acid (L)-4-dihydroxy-borylphenylalanine,
known as boronophenylalanine or BPA [10]. Neither of
these agents adequately fulfills the criteria indicated above,
and for this reason third generation agents incorporating
one or more polyhedral borane anions or carboranes have
been investigated. With the development of new synthetic
techniques and increased awareness of the biochemical
requirements needed for effective boron containing agents
and their modes of delivery, a number of new boron agents
have emerged. The major challenge in the development of
such agents has been the requirement for selective tumor
cell targeting and the delivery of therapeutic boron levels
with minimal normal tissue toxicity. The localized and
effective destruction of glioblastoma (GBM) cells in the
presence of normal brain represents a greater challenge
than for malignancies at other anatomic sites. This is due
to an additional biological barrier, the blood–brain barrier
(BBB), and the highly infiltrative nature of glioma cells and
their molecular heterogeneity.
Third generation boron delivery agents
Recent efforts to improve the selectivity of boron deliv-
ery agents has involved incorporating them into tumor-
targeting molecules, such as peptides, proteins, anti-
bodies, nucleosides, sugars, porphyrins, liposomes and
nanoparticles. A compilation of third generation delivery
agents of low and high molecular weight is summarized
in Table 1 and a recent comprehensive review on this
topic [11]. The low molecular weight boron delivery
agents include boronated natural amino acids (i.e., BPA
derivatives with higher percentage of boron by weight)
as well as boronated derivatives of other amino acids,
such as aspartic acid, tyrosine, cysteine, methionine and
serine [12-14]. Additionally, boron-containing unnatural
amino acids also have been investigated because of their
higher metabolic stability compared with the natural
ones. The boronated derivatives of 1-aminocyclobutane-
1-carboxylic acid and 1-amino-3-boronocyclopentane-
carboxylic acid (designated ABCPC) are examples of
such compounds [13,14]. Boron-containing linear and
cyclic peptides are being investigated because they are
usually non-immunogenic, easy to synthesize, and often
show low toxicity and high tissue penetrating properties
[15]. Of particular interest are peptide ligands for over-
expressed receptors on tumor cells, such as the vascular
endothelial growth factor receptor (VEGFR), somato-
statin receptors and the epidermal growth factor
Table 1 Examples of new low- and high-molecular-weight
boron delivery agents currently under evaluation*
Boronated unnatural amino
acids [12-14]
Carboranyl nucleosides [16,17]
Dodecaborate cluster lipids and
cholesterol derivatives [18]
Boronated porphyrins [19-21]
Boron containing immunoliposomes
[22] and liposomes [23-26]
Boronated EGF and anti-EGFR
and VEGFR MoAbs [27-33]
Boronated DNA intercalators [34] Boron-containing nanoparticles
[35,36]
Transferrin–polyethylene glycol
(TF–PEG) liposomes [37,38]
Carboranyl porphyrazines [39]
Dodecahyrdo-closo-dodecaborate
clusters [18]
Boronated cyclic peptides [15]
Boron nitride nanotubes [40]
* The numbers indicated in brackets are cited in the reference section.
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livery sequences.
Boron-containing purines, pyrimidines, thymidines,
nucleosides and nucleotides have also been investigated
as BNCT delivery agents [16,17,41], in particularly 3-
carboranyl thymidines (3CTAs). For example, the thymi-
dine derivative designated N5-2OH displays selective
tumor uptake, a high rate of phosphorylation and low
toxicity [16]. Convection enhanced delivery (CED) of
N5-2OH to rats bearing intracerebral RG2 gliomas has
been effective for the selective delivery of therapeutic
concentrations of boron to tumors with very high
tumor:brain and tumor:blood ratios without any con-
comitant toxicity [17].
Boron-containing porphyrin derivatives (porphyrins,
chlorins, bacteriochlorins, tetrabenzoporphyrins, and
phthalocyanines) have been extensively investigated due
to their usually low toxicity and natural affinity for
tumors [19,20]. Examples of such compounds are BOPP
[21], CuTCPH, and H2OCP. Porphyrin derivatives have
been shown to deliver therapeutic amounts of boron to
tumor bearing mice and rats. They attained high tumor:
brain and tumor:blood boron concentration ratios, and
longer retention times in tumors than BSH and BPA. In
addition, boron-containing chlorins, bacteriochlorins
and phthalocyanines are promising dual agents for both
BNCT and photodynamic therapy (PDT) of tumors.
Two of these porphyrin derivatives have been FDA-
approved as photosensitizers for PDT. This is due to the
strong absorptions of these macrocycles in the red and
near-infrared regions of the optical spectrum, and their
unique photosensitizing properties [19]. Other boron-
containing DNA binding molecules, including alkylating
agents, DNA intercalators, minor-groove binders and
polyamines have been investigated [34]. For example,
derivatives of aziridines, acridines, phenanthridines, vari-
ous Pt(II) complexes and carboranylpolyamines have
been described. These compounds sometimes show low
tumor selectivity and significant toxicity, in part due to
their multiple cationic charges and/or ability for binding
to DNA of normal cells. Boron-containing sugars, includ-
ing derivatives of glucose, mannose, ribose, galactose, mal-
tose and lactose have also been investigated [11,42]. This
class of molecules usually displays low toxicity and low
tumor uptake, in part due to their hydrophilicity and fast
clearance from tissues.
Among the high molecular weight boron delivery
agents, monoclonal antibodies (MoAbs), liposomes and
nanoparticles are the most common. MoAbs are a very
promising class of tumor-targeting agents due to their
high specificity for molecular targets such as EGFR and
VEGFR [27-30]. Extensive studies have been carried out
by Barth, Wu and Yang and their co-workers using a
heavily boronated precision macromolecule that has
been linked by means of heterobifunctional reagents to ei-
ther the EGFR targeting MoAb cetuximab (Erbitux
TM)
[28], the EGFRvIII targeting MoAb L8A4 [31] or EGF itself
[32]. These nanovehicles (NVs) have been administered
intracerebrally (i.c.) by means of convection enhanced de-
livery (CED) to rats bearing receptor positive F98 gliomas,
followed by BNCT [28,29,31-33]. The best survival data
were obtained in F98 glioma bearing rats when these NVs
were combined with intravenous or intra-arterial adminis-
tration of BPA and BSH [28,29,31,33] yielding a 2–3f o l d
increase in mean survival times (MST) compared to irra-
diated controls.
Immunoliposomes can deliver low molecular weight
hydrophobic agents, such as BSH, via incorporation into
their lipid bilayers [22,23]. Liposomes can also transport
large numbers of boronated molecules intracellularly and
normally show high tumor boron uptake [24]. Hawthorne,
Feakes and their co-workers have extensively investigated
liposomes as BNCT delivery agents of a variety of poly-
hedral boron anions and these studies were recently
reviewed [25]. High tumor boron concentrations were
attained in vitro when polyhedral boron anions are
encapsulated in tumor-selective unilamellar liposomes,
but in vivo their therapeutic efficacy has yet to be demon-
strated. Linkage of boron-containing liposomes to the
MoAb cetuximab resulted in specific molecular targeting
of the immunoliposomes to EGFR expressing F98 glioma
cells [22]. Boron-containing lipids bearing covalently-
bound boron clusters also have been reported. These
nanoparticles have the advantages of showing no leakage
of encapsulated boronated compounds, delivering high
concentrations of boron to tumor-bearing mice, and in-
creasing survival times following BNCT [26,37]. Add-
itional classes of boron-containing nanoparticles have
been investigated as BNCT delivery agents [35,40] and
this work has been recently reviewed [36].
Neutron sources for BNCT
As described in more detail later in this review, clinical
studies on BNCT originated at the Brookhaven National
Laboratory (BNL) and the Massachusetts Institute of
Technology (MIT) in collaboration with the Massachusetts
General Hospital (MGH) approximately 60 years ago [2].
The initial trials for the treatment of high grade gliomas
were carried out with fission reactor-produced beams of
thermal neutrons. The inadequate penetration of tissue by
thermal neutrons, 3-4 cm, led the clinical team in the
MIT/Harvard trials to introduce intra-operative, open cra-
nium irradiations with an air-filled balloon inserted into
the surgical cavity to increase neutron penetration and
avoid excessive dose to the scalp. After a hiatus of almost
25 years, more recent clinical trials were initiated at MIT
and BNL, in the early 1990’s, using for the first time
higher energy neutrons in the epithermal energy range
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obviated the need for intra-operative BNCT when treating
deep seated malignancies. Epithermal neutrons, for ex-
ample, can reach tumors at the midline of the brain at a
d e p t ho f~ 8c mw i t ht h e r a p e u t i cr a t i o s> 1 .E p i t h e r m a l
neutrons are now generally used in BNCT irradiations
although some intra-operative irradiations with thermal
neutrons are still performed. Reactor-based facilities in
Japan are capable of producing various mixtures of
thermal and epithermal neutron spectra, which can
be advantageous for head and neck cancers where
deep beam penetration may not be required.
Fission reactor sources for NCT
The general characteristics of neutron beams for NCT are
described in detail elsewhere [43] and the requirements for
a facility capable of high patient through-put have been dis-
cussed by Harling [44]. Two approaches have been used for
the design of epithermal neutron irradiation facilities at fis-
sion reactors. Direct use of the core neutrons as the source
has been the predominant approach for modification or
conversion of existing reactors for NCT. More than eight
such facilities have been constructed for clinical use in the
Americas, Europe and Asia and several more are under
construction. Performance characteristics for many of these
facilities have been summarized in a review by Harling and
Riley [45]. An interesting new facility, which makes direct
use of core neutrons from a low power reactor, was recently
constructed in China and is located in a suburb of Beijing
[46,47]. This is the first reactor designed specifically for
NCTand is based on an ultra-safe, low cost design specially
suited for urban populated areas or within a hospital.
Another approach to using fission reactors is based
upon the use of a fission converter which converts a reac-
tor’s thermal neutrons to higher energy fission neutrons.
The fission neutrons are then moderated and filtered to
produce epithermal neutron beams. This approach can be
especially useful to modify existing multipurpose reactors.
One fission converter based facility, called the FCB
(Figure 1) has been constructed at the MIT Research
Reactor (MITR) [48,49]. The MIT FCB represents the
current state of the art for epithermal neutron irradiation
facilities. It meets all requirements for an epithermal
neutron irradiation facility needed for routine high
throughput clinical NCT. Features and capabilities of the
MIT FCB include high intensity, 10–15 minutes to deliver
a tolerance dose per irradiation field, accurate delivery of
the prescribed neutron fluence, low beam contamination
from adventitious radiation components and easy beam
positioning on any part of the body. Therapeutic ratios
above unity are achieved for depths up to 10 cm using the
currently available drug, BPA.
Unless BNCT becomes more broadly accepted as a
treatment modality for specific cancers, the need to
develop additional nuclear reactors remains limited and
further construction seems unlikely. New, special purpose
reactors like the one in China, which is still not in clinical
use, are a possible source of additional neutron irradiation
facilities. Additional reactor conversions and modifications
also can be undertaken using proven approaches that re-
quire very little research and development effort.
Accelerator based neutron sources (ABNSs)
To date, all BNCT clinical irradiations have used fission
reactor neutron sources, however accelerator based neu-
tron sources are under development and may eventually
provide another option to fission reactors. Accelerator
based neutron sources are being developed for use in
NCT with the anticipation of being easier to site in hos-
pitals and license than a dedicated nuclear reactor. Pro-
ponents of accelerators also believe that they could be
more compact and less expensive than comparable re-
actor sources. ABNSs for BNCT have been reviewed in
detail elsewhere [50,51]. Generally they produce low in-
tensity neutron fluxes compared to reactor sources and
this has been a problem for implementation. An increase
in intensity by more than an order of magnitude would
be necessary if accelerators are to be competitive with
the better reactor sources for clinical BNCT. An ABNS
recently has been constructed by Sumitomo Heavy In-
dustries and approval for clinical use has been granted
by the Pharmaceutical and Medical Safety Bureau of the
Japanese Ministry of Health, Labour, and Welfare [52]. It
is anticipated that clinical trials will be initiated in 2013
using this ABNS. Finally, an 8 MeV, 10 mA linac system
is under construction and this should be completed in
two years (A. Matsumura, Personal Communication).
Clinical dosimetry and treatment planning
Clinical studies in BNCT have thus far been run usually
as single cohorts of patients at individual centers spread
across the world. These consisted mainly of Phase I/II
trials to establish normal tissue tolerance and secondar-
ily to demonstrate some possible therapeutic efficacy.
Each center has, by necessity, developed their own meth-
ods to measure, calculate and prescribe absorbed doses
for these trials through their own extramural research
programs, and this limits their applicability to the local
center where they were obtained. After more than 50 years,
BNCT still remains, for the most part, an experimental
modality with no standardized methods for either calibrat-
ing the mixed radiation fields employed or for calculating
treatment plans that specify the patient prescription. This
lack of uniformity hinders comparison of clinical results
from different centers because it precludes combining or
sharing clinical data on safety and efficacy in any mean-
ingful way, which should be addressed if BNCT is to have
a larger clinical role.
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cated by the presence of photon and fast neutron dose
components in the radiation field, each possessing a
markedly different biological effectiveness that must be
quantified separately. In order to account for the varying
biological effectiveness of the dose components, multi-
plicative weighting factors have been applied to the indi-
vidual dose components to allow expression of their
sum as a single, total weighted dose (expressed as Gyw),
which is approximately equivalent in effect to the same
dose of photon radiation. These weighting factors gener-
ally have been RBE (relative biological effectiveness) fac-
tors measured in animal models [53]. A few common
dosimetric methods have been developed to determine
the principal absorbed dose components contributed by
boron and other low energy neutron capture reactions
with normal tissue hydrogen and nitrogen. These dose
components generally are determined from absolute mea-
surements of the thermal neutron flux obtained by neu-
tron activation analysis of bare and cadmium-covered
gold foils [54,55]. Gamma rays emitted by the activated
foils are counted using a gamma spectrometer incorporat-
ing either a high-purity germanium or sodium iodide de-
tector with a calibration traceable to a national standards
laboratory. The measured thermal neutron flux is multi-
plied by the appropriate kerma coefficient for a given reac-
tion and the assumed weight fraction of boron (or
nitrogen) in the tissue that is being irradiated. Similarly, the
twin ionization chamber technique [56], developed for fast
neutron therapy [57], is often applied as the method of
choice for assessing the adventitious dose arising from both
the incident and induced photons as well as fast neutrons
contaminating low energy neutron beams. Pairs of detec-
tors are employed with different sensitivities to the two ra-
diation types such as A-150 tissue equivalent plastic- and
graphite- (or magnesium-) walled ionization chambers.
Treatment planning for NCT differs markedly from
that of conventional radiotherapy and in some ways it is
significantly more complex, requiring specialized software
[58-61]. NCT treatment planning systems rely exclusively
on Monte Carlo simulations for dose calculations because
of the complex, scatter-dominated nature of neutron
transport. The Monte Carlo method simulates transport
of neutrons and photons through the patient’sg e o m e t r y
and uses track-length density estimators of neutron and
photon flux integrated against energy-dependent kerma
coefficients to compute dose. Treatment planning systems
require careful validation by evaluating agreement
Figure 1 Schematic diagram of the Massachusetts Institute of Technology Reactor (MITR). The fission converter based epithermal neutron
irradiation (FCB) facility is housed in the experimental hall of the MITR and operates in parallel with other user applications. The FCB contains an array of 11
M I T R - I If u e le l e m e n t sc o o l e db yf o r c e dc o n v e c t i o n of heavy water coolant. The converter power is 120 kW at 6 MW reactor power. A shielded horizontal
beam line contains an aluminum and Teflon
W filter-moderator to tailor the neutron energy spectrum into the desired epithermal energy range. A patient
collimator defines the beam aperture and extends into the shielded medical room to provide circular apertures ranging from 16 to 8 cm in diameter.
The in-air epithermal flux is 6.2×10
9 n/cm
2s at the patient position with the 12 cm collimator. The measured specific absorbed doses are constant for all
field sizes and are well below the inherent background of 2.8×10
-12 Gywcm
2/n produced by epithermal neutrons in tissue. The dose distributions
achieved with the FCB approach the theoretical optimum for BNCT. This facility is useful for clinical studies of superficial cancers and small animal studies.
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[62,63]. Treatment planning calculations use individua-
lized computational models of the target, constructed
from CT or MR images. While electron density is the
principal consideration for transport of megavoltage pho-
ton beams in tissue, neutron transport is governed by
nuclear interactions. Since neutron cross sections vary sig-
nificantly between elements, NCT dose calculations must
model the elemental compositions of different tissue types
in the region of interest. Concentrations of hydrogen, ni-
trogen, and boron have the most influence on neutron
transport and dosimetry.
BNCT treatment plans are typically presented as total
weighted doses, as shown in Figure 2 for tumor and
normal tissue(s) and each is calculated separately for the
entire dose grid using boron concentrations and weight-
ing factors (RBEs) assumed for each tissue. The rationale
for this approach is that the exact boundary of the
tumor is unknown and that microscopic deposits of
tumor extend well beyond the enhancing volume detect-
able by imaging. Generally, the tumor and tissue boron
concentrations used for dose calculations in treatment
planning are assessed as the product of blood boron
concentrations measured for the patient at the time of
irradiation and static tissue:blood boron concentration
ratios determined in previous studies. For example, with
BPA-fructose (BPA-F) common assumptions for tissue:
blood boron concentration for tumor, normal brain, and
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Figure 2 A three-field treatment plan for a brain tumor (GBM) patient calculated using the MiMMC treatment planning system. The
prescription is a mean brain dose of 7.7 Gyw. Isodose contours calculated for tumor and normal brain are shown on axial and sagittal slices through the
target volumes. The integral dose volume histograms (DVHs) summarize dosimetry for structures of interest including target volumes and organs at risk.
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and 4, in cases where [
18F]BPA-F PET scans [64] are
available, these data often are incorporated into the
treatment plan and used to estimate the spatial distribu-
tion of boron in dose calculations. Application of [
18F]
BPA-F PET data to dosimetry must, however, be inter-
preted with caution because of considerations such as
the low spatial resolution and volume averaging
effects of the PET scan as well as differences between
the bolus injection of radiotracer and the large vol-
ume infusion of BPA-F that occurs over an extended
time for treatment.
Although most BNCT centers use some variant of
these dosimetry and treatment planning methods, it is
important to recognize that while the individual centers
achieve satisfactory consistency or precision within par-
ticular patient cohorts, dose specifications vary consider-
ably in absolute terms between centers. An extensive
series of comparisons was performed between all clinical
centers in the Americas and Europe [63,66-69] that
found variations ranging between 7.6 and 13.2 Gyw for a
common dose specification of 10 Gyw as defined in the
Harvard-MIT clinical trials. The magnitude and range of
these variations, illustrated in Figure 5 for several facilities,
cannot be fully explained by experimental uncertainties or
measurement errors. These variations exclude possible sys-
tematic differences related to biological weighting factors.
Rather, these findings highlight specific implementation
problems such as beam source definitions [70] or inexact
benchmarking of treatment planning systems [62,71] that
only become apparent when comparing between centers.
The infrastructure and expense associated with founding
and running trials has to date been significant, but even
larger and more definitive patient trials are still needed to
conclusively demonstrate efficacy, especially in patients
with high grade gliomas. This is likely beyond the means of
any single center and will only be possible through
collaborative clinical trials run by multiple institutions. As
a prerequisite, the NCT research community needs to
recognize the importance of quantifying and establishing
dose uniformity between centers and prioritize these
endeavors if larger multi center trials are to succeed.
Clinical studies of BNCT for brain tumors utilizing thermal
neutron beams
The clinical potential of BNCT first was recognized by
Locher [72] shortly after the discovery of the neutron.
However, it was not until 1951 that the first clinical trials
were initiated by Sweet at the Massachusetts General
Hospital (MGH) and Brownell at MIT [73] and Farr at
the Brookhaven National Laboratory (BNL) in New York
[74] using sodium tetraborate (borax), sodium pentabo-
rate, p-carboxyphenylboronic acid, or sodium decahy-
drodecaborate (Na2B10H10) as the sole boron delivery
agent. However, since these studies utilized thermal neu-
tron beams they will not be discussed here. Interested
readers are referred to a comprehensive review describ-
ing these studies in detail [2], as well as reports by Farr
Figure 3 Contrast-enhanced T1-weighted MRI of representative glioblastoma patient and
18F-labeled BPA-PET image after initial
debulking surgery. The patients received
18F-BPA-PET to assess the distribution of BPA and to estimate the boron concentration in tumors before
BNCT without direct determination of boron concentration in the tumor. The lesion to normal brain (L/N) ratio of the enhanced tumor was 7.8 in this
case. Note that even the periphery of the main mass, i.e., the infiltrative portion of the tumor, showed BPA uptake. The L/N ratio of BPA uptake can be
estimated from this study and dose planning was done according to this L/N ratio, and if the L/N ratio was more than 2.5, then BNCT was initiated.
18F-BPA-PET accurate BPA provided an accurate estimate of the accumulation and distribution of BPA as previously reported [64,65].
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Hatanaka [76] and later Hatanaka and Nakagawa [77]
carried out extensive studies in Japan using BSH as the
boron delivery agent [78]. Again these studies also used
thermal neutron beams, and therefore they will not be
discussed in the present review. However, interested
readers are referred to articles of Hatanaka [76] and
Nakagawa [77], as well as those of other Japanese neuro-
surgeons who utilized thermal neutron beams.
Clinical trials carried out in the United States
Clinical trials were again initiated in the United States util-
izing epithermal neutron beams in the 1990s when BNCT
was resumed at the BNL Medical Research Reactor
(BMRR) [79,80] and at Harvard-MIT using the MITR
[81]. In a major step forward, BPA was used as the boron
delivery agent and, for the first time, patients were irra-
diated with a collimated beam of higher energy epithermal
neutrons in two fractions on consecutive days. These had
greater tissue-penetrating properties than thermal neu-
trons and were well tolerated. These trials benefited from
a number of other technological developments that oc-
curred over the intervening decades: Monte Carlo treat-
ment planning and dosimetry based on tomographic
imaging, accurate physical dosimetry techniques, rapid and
reliable boron analysis techniques, and an improved under-
standing of the radiobiology of BNCT. The median survival
times of patients that had received a single treatment with
BNCT were equivalent to those receiving conventional,
fractionated radiation therapy [80,81]. Furthermore, these
trials established the safety of the new procedure and
this set the stage for the use of BPA in combination with
epithermal neutrons as the new standard. This subse-
quently was adopted by clinicians in Japan and Finland
for the treatment of patients with high grade gliomas.
Worldwide clinical experience using BNCT with epither-
mal neutrons to treat high grade gliomas and other
brain tumors is summarized in Tables 2 and 3.
Clinical trials in Japan
Kawabata and Miyatake and their clinical team have carried
out several studies in which either BPA alone or in combin-
ation with BSH have been used for BNCT [101-103,106].
The patients had either primary, surgically resected gliomas
or recurrent GBMs who had previously received X-irradi-
ation. Favorable responses were seen in patients with
newly diagnosed GBMs, especially those in high risk
groups [102], using BPA and BSH either with or without
an X-ray boost. Patients treated with surgery and BNCT
using 100 mg/kg BSH infused over 1 h and 700 mg/kg
BPA infused over 6 h followed by 20-30 Gy of fractionated
X-rays (Protocol 2) had a median survival time (MeST) of
23.5 months compared to 14.1 mos. for those who had
s u r g e r yf o l l o w e db yB N C Tu s i n g1 0 0m g / k gB S Ha n d
a lower dose of BPA, 250 mg/kg infused over 1 h
(protocol 1) (Figure 6). The composite MeST of patients
who had surgery and BNCT (with or without X-rays)
(n=21), was 15.6 mos. (95% confidence interval (CI):
12.2-23.9 mos. This was significantly longer than 10.3
mos. for historical controls (n=27) at the Osaka Medical
College who had surgery followed by radiation therapy
and chemotherapy with ACNU [106]. These clinical stud-
ies have validated the animal model data of Barth et al.
showing an increase in MSTs of F98 glioma bearing rats
by combining BNCT with X-irradiation [107]. Predicting
which patients might be more likely to respond to BNCT
would be a major step forward. Fluorine-18 labeled BPA
has been used to predict the effectiveness of BNCT
[64,65], as well as to detect post treatment radiation
effects [65]. Representative radiographic changes seen in
Figure 4
18FDG-PET study prior and 6 months after BNCT of a 56 year-old male patient with recurrent squamous cell carcinoma of the
maxilla. A: FDG accumulated in the left orbital region (arrows) and frontal lobe of brain (arrow heads). B: No accumulation of FDG-PET was
detected 6 months after BNCT and the patient was disease free for 61 months at the time of the original report. Photographs are from Applied
Radiation and Isotopes, 67:S37-S42, 2009.
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http://www.ro-journal.com/content/7/1/146two patients, treated by BNCT, are shown in Figure 7 and
PET imaging studies with
18F-BPA are shown in Figure 3.
Although retrospective comparisons must be interpreted
with caution, the MeST from the date of diagnosis, calcu-
lated using the Kaplan-Meier method (Figure 6), for
historical controls was 10.3 months (95% CI: 7.4-13.2, log-
rank test p=0.0035) compared to 23.5 months (95% CI:
10. 2 mos. to undetermined) after diagnosis (n=11), for
patients treated with BNCT plus X-irradiation. However,
the MeST of patients in Protocol 1 (BNCT-XRT) was
14.1 months (95% CI: 9.9 mos.-18.5 mos.), which was
not significantly different from historical controls, but
this may be attributable to low patient numbers since
they were subdivided into two protocols involving only
10 and 11 patients each. Kawabata, Miyatake and their
co-workers plan to evaluate BNCT in combination with
temozolomide in a multicenter Phase II Japanese clin-
ical study (OSAKA-TRIBRAIN0902, NCT00974987).
Finally, extensive studies also have been carried out by
Matsumura and his clinical team at the University Hos-
pital of Tsukuba [108-110] using either BPA or BSH
alone or in combination as the boron delivery agents
(see Table 3). In some cases BNCT was combined with
a photon boost in combination with temozolomide in
patients with either primary or recurrent GBMs. The
approach used mosst recently at the University of Tsu-
kuba, using BPA in combination with BSH, followed by
a fractionated photon boost, has resulted in the most
favorable survival achieved with BNCT to date: 27.1
mos. MeST with a 2 year OS of 63% (n=8)[109,110].
However, these results must be interpreted, with cau-
tion due to the very small number of patients that have
been treated. A randomized Phase II clinical trial with a
sufficient number of patients will be required to valid-
ate these very encouraging but preliminary results.
Clinical studies in Finland
Kankaanranta et al. at the Helsinki University Central
Hospital and VTT Technical Research Center of Finland
have reported on 22 patients with GBMs who had
undergone standard therapy, recurred, and subsequently
received BNCT at the time of their recurrence using
BPA as the boron delivery agent [88]. The overall MeST
was 7 mos. and the median time to progression was 3
mos. However, it is difficult to compare these survival
data and those reported for patients with recurrent
GBMs receiving conventional treatments. Nevertheless,
they are a starting point for future studies using BNCT
as salvage therapy in patients with recurrent tumors.
EORTC clinical study
APhase I clinical trial was carried out by the European
Organization for Research and Treatment of Cancer to
evaluate BSH as a boron delivery agent (protocol #11961)
using the High Flux Reactor at Petten, the Netherlands.
The aims of this study were to investigate the systemic
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Figure 5 Graphical representation of a parameterized model converting the maximum weighted dose, calculated Treatment Planning
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and direct comparison of dose specification between participants of the International Dosimetry Exchange.
Barth et al. Radiation Oncology 2012, 7:146 Page 9 of 21
http://www.ro-journal.com/content/7/1/146Table 2 BNCT clinical trials in the United States and Europe using epithermal neutron beams for patients with brain tumors
Medical institution Neutron source Treatment
dates
Tumor type & No. of
patients
a
Boron compound &
treatment
b
Clinical outcome
c Ref.
Brookhaven National Laboratory,
Upton, NY, USA
Brookhaven Medical Research Reactor,
BNL, Upton, NY, USA
1994-1999 GBM 53 BPA 250–330 mg/kg in 2 h MeST: 12.8 mos. [53,79,80,82]
2 y OS: 9.4%
Beth Israel Deaconess Medical
Center, Harvard Medical School,
Boston, USA
MIT Research Reactor, Massachusetts
Institute of Technology, Cambridge, USA
1996-1999 20 GBM BPA 250–350 mg/kg in 1.5 h MeST: 11.1 mos (n=18) [53,59,81]
2 IC MM 2 y OS: 12%
2002-2003 6 GBM BPA 14 g/m
2 in 1.5 h NA [61]
Universitätsklinikum Essen, Essen
Germany
High Flux Reactor, JRC Petten, The
Netherlands
1997-2002 26 GBM BSH 100 mg/kg in 1.7 h MeST: 10.4-13.2 mos. [83,84]
2004-2006 4 IC MM (>20 IC mets ea.) BPA 14 g/m
2 in 1.5 h OS: < 3 mos. [85]
Helsinki University Central Hospital,
Helsinki, Finland
FiR-1, VTT Technical Research Centre,
Espoo, Finland
1999-2001 30 GBM BPA 290–500 mg/kg in 2 h MeST: 11.0-21.9 mos. [86,87]
2001-2008 20 rGBM BPA 290–450 mg/kg in 2 h MeST: 7 mos. post BNCT [88]
2 rAA 1 y OS: 36%
2yO S :0 %
Faculty Hospital of Charles University,
Prague, Czech Republic
LVR-15 Reactor, Nuclear Research
Institute Rez, Czech Republic
2000-2002 5 GBM BSH 100 mg/kg in 1 h NA [89]
Nyköping Hospital, Nyköping,
Sweden
R2-0 Reactor, Studsvik Medical,
Nyköping, Sweden
2001-2003 29 GBM BPA 900 mg/kg in 6 h MeST: 17.7 mos. [90-93]
2 y OS: 14%
2003-2004 1 rMMng BPA 900 mg/kg in 6 h OS: 32, 26+ mos. post BNCT [94]
1 rMC
2001-2005 12 rGBM BPA 900 mg/kg in 6 h MeST: 8.7 mos. post BNCT [95]
aIncluding other disease sites and patients treated off-protocol, the total number of patients treated at some reactors is much greater than reported here, for FiR-1, ~260, for KURR, >107, and for JRR-4, >200 patients.
bTreatment is indicated only in cases when it is not solely external beam BNCT.
cA range of survival is given in some cases to summarize survival reported for different cohorts.
Abbreviations: r recurrent, GBM glioblastoma multiforme, IC MM intracranial metastatic melanoma, AA anaplastic astrocytoma, MMng malignant meningioma, MC mesenchymal chondrosarcoma, AOA anaplastic
oligoastrocytoma, MRM meningioma related malignancy, IO-BNCT intraoperative BNCT, XRT external beam radiation therapy (photons), MeST median survival time, 2yO S2 year overall survival, RI radiographic
improvement, NA not available.
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6toxicity of i.v. administration of BSH, the maximum toler-
ated radiation dose and the dose limiting toxicity of
BNCT. At the time of reporting [83,84] a total of 26
patients had been treated with BNCT with a starting dose
of 8.6 Gy. In all but one patient, BNCT was performed in
4 fractions on 4 consecutive days. On the day prior to the
first irradiation BSH (100 mg/kg b.w.) was administered
i.v. Both the amount administered and the time from BSH
infusion to irradiation (range 8–14 h) were adjusted to
achieve a blood boron concentration of~30 μg/g during
irradiation. The MeST of the first patient group was
10.4 months after the first surgery, 11.3 months for the
second group and 13.2 months for the third patient group
[83]. However, dose limiting toxicities were observed in
this study [84].These mainly consisted of cerebral atrophy
and white matter abnormalities [84].
Clinical studies in Sweden
We would like to conclude this section on BNCT of high
grade gliomas with a summary of a clinical trial that was
carried out in Sweden using BPA and an epithermal neu-
tron beam. This study differed significantly from all previ-
ous clinical trials in that the total amount of BPA infused
was increased to 900 mg/kg b.w., and it was given i.v.
over 6 hours [90]. This regimen was based on animal
studies in F98 glioma bearing rats that showed that boron
concentrations in invading tumor cells increased from
37% to 71% of that in the main tumor if the infusion time
was increased from 2 h to 6 h [111]. The higher dose and
longer infusion time of the BPA were well tolerated by the
29 patients who were enrolled in this study [90-93,112].
The minimum dose to the tumor ranged from 15.4 to
54.3 Gyw and the mean weighted dose to whole brain was
3.2-6.1 Gyw and all were treated with 2 fields. There has
been some disagreement among the Swedish investigators
who carried out this study on evaluation of the results.
One group reported survival data that was compiled be-
fore all of the patients had succumbed to their tumors
[91]. Based on all of the survival data, another group
[92,93,112] determined that the MeST was 17.7 mos.
compared to 15.5 mos. for patients who received standard
therapy of surgery, followed by radiotherapy (RT) and
temozolomide. Furthermore, the frequency of adverse
events were lower after BNCT (14%) than after RT alone
(21%) and both of these were lower than those seen fol-
lowing RT in combination with temozolomide. If these
improved survival data, using a 6-hour infusion time and
a higher dose of BPA, can be confirmed by others, prefer-
ably in a randomized clinical trial, it could represent a sig-
nificant step forward in BNCT of brain tumors, especially
if combined with a photon boost.
Clinical studies of BNCT for head and neck cancer
Studies carried out in Japan
The use of BNCT to treat patients with recurrent cancers
of the head and neck region who had failed all other ther-
apies was first initiated in 2001 by Kato and his co-workers
in Japan [5] at the Kyoto University Research Reactor Insti-
tute (KURRI). The rationale for this was based on the abil-
ity of BNCT to deliver a large additional dose of radiation
to the site of the tumor with a sparing of contiguous nor-
mal tissues. The first patient treated had a recurrent
mucoepidermoid carcinoma of the parotid gland. Locore-
gional control was achieved and she died 7 years later of
unrelated disease (Figure 8). Similar, clinically impressive
results were seen in other patients treated by Kato et al. [5]
and
18F-BPA and
18F-FDG PET scans from two patients
are shown in Figures 9 and 4, respectively. Kato et al. sur-
vival data are summarized in the Kaplan-Meier plots
shown in Figure 10. Based on these promising results two
independent clinical trials were initiated in Japan by Kato
Figure 6 A. Kaplan-Meier estimates of overall survival for all
newly diagnosed glioblastoma (WHO grade 4, n=21). The
median survival time of boron neutron capture therapy (BNCT)
group (blue line) is 15.6 months. There is statistical significance
between both group Log-rank test (p=0.0035). B. Kaplan-Meier
estimates of overall survival for all newly diagnosed glioblastoma
(protocol 1 and 2). External beam X-ray irradiation (XRT) boost after
boron neutron capture therapy (BNCT) was carried for the latter 11
cases. This improved the median survival time to 23.5 months (from
14.1 months for BNCT only, protocol 1, dotted line in blue).
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http://www.ro-journal.com/content/7/1/146Table 3 BNCT clinical trials in Japan using epithermal or mixed thermal & epithermal neutron beams for patients with brain tumors
Medical institution Neutron source Treatment
dates
Tumor type & No. of
patients
a
Boron compound &
treatment
b
Clinical outcome Ref.
University of Tsukuba, Tsukuba City,
Ibaraki, Japan
JRR-4, Japan Atomic Energy Agency,
Tokai, Ibaraki, Japan
1999-2002 5 GBM BSH 100 mg/kg in 1–1.5 h MeST: 23.2 mos. (GBM) [96]
4 AA IO-BNCT MeST: 25.9 mos. (AA)
1998-2007 7 GBM BSH 5 g in 1 h, IO-BNCT MeST: 23.3 mos. [97]
2 y OS: 43%
1998-2007 8 GBM BSH 5 g in 1 h & BPA
250 mg/kg in 1 h
MeST: 27.1 mos. [97]
2 y OS: 63%
BNCT+XRT
University of Tokushima, Tokushima,
Japan
JRR-4 or KURR (Kyoto University Research
Reactor, Osaka, Japan)
1998-2000 6 GBM BSH 64.9-178.6 mg/kg MeST: 15.5 mos. [98-100]
IO-BNCT 2 y OS: 0%
2001-2004 11 GBM BSH 64.9-178.6 mg/kg MeST: 19.5 mos. [98-100]
IO-BNCT 2 y OS: 27%
2005-2008 6 GBM BSH 100 mg/kg & BPA
250 mg/kg
MeST: 26.2 mos. [98-100]
2 y OS: 50%
BNCT+XRT
Osaka Medical College, Osaka, Japan KURR 2002-2003 10 GBM BSH 5 g & BPA 250 mg/kg in
1h
MeST: 14.5 mos. [101,102]
2 y OS: 20%
2003-2006 11 GBM BSH 5 g & BPA 700 mg/kg in
6h
MeST: 23.5 mos. [102]
2 y OS: 27.3%
BNCT+XRT
2002-2007 19 rGBM BSH 100 mg/kg & BPA
250 mg/kg in 1 h or
MeST: 10.8 mos. post BNCT [103]
2 rAA, 1 rAOA
BSH 100 mg/kg & BPA
700 mg/kg in 6 h
2 y OS: 14%
2005-2006 7 rMRM BSH 0–5 g RI: 100% [104,105]
BPA 500–700 mg/kg in 3–4h
aIncluding other disease sites and patients treated off-protocol, the total number of patients treated at some reactors is much greater than reported here, for FiR-1, ~260, for KURR, >107, and for JRR-4, >200 patients.
bTreatment is indicated only in cases when it is not solely external beam BNCT.
Abbreviations: r recurrent, GBM glioblastoma multiforme, IC MM intracranial metastatic melanoma, AA anaplastic astrocytoma, MMng malignant meningioma, MC mesenchymal chondrosarcoma, AOA anaplastic
oligoastrocytoma, MRM meningioma related malignancy, IO-BNCT intraoperative BNCT, XRT external beam radiation therapy (photons), MeST median survival time, 2yO S2 year overall survival, RI radiographic
improvement, NA not available.
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6and Suzuki and their respective teams to evaluate the safety
and efficacy of BNCT in patients with a variety of malig-
nancies of the head and neck region and these are sum-
m a r i z e di nF i g u r e s1 0a n d1 1a n dT a b l e4 .At o t a lo f6 8
patients with either newly diagnosed or recurrent, thera-
peutically refractory tumors were treated by Suzuki et al.
between December 2001 and September 2007 (Figure 11).
BPA and BSH, either alone or in combination, were used
as the capture agents with either single or multiple applica-
tions of BNCT. Initially, BPA was administered i.v. at a
dose of 250 or 500 mg/kg over 1–2 h, followed by BNCT
using an epithermal beam within 15 min after termination
of the infusion of BPA. Beginning in June 2004, BPA was
infused at a dose of 500 mg/kg over 3 h at a rate of
200 mg/kg h for the first 2 h, and then at a rate of 100 mg/
kg h for the final hour during which time the patient
received BNCT. For patients who had received both BSH
and BPA, epithermal neutron irradiation was initiated
12 h after termination of the infusion of BSH and one
hour after that of BPA. The duration of BNCT was
adjusted so that the majority of the cases the maximum
radiation dose to the surrounding skin and normal tissue
would be <10-12 Gyw.
Patient population and treatment results
All of Suzuki’s patients had unresectable advanced or re-
current cancers of the head and neck region. Forty-nine
patients (79%) had recurrent tumors and 13 (21%) had
newly diagnosed unresectable tumors. Among the 49
patients, 39 (80%) had previous chemotherapy, 41 (84%)
had previous surgical resection, and 36 (73%) had previous
radiotherapy. Treatment sites included the oral and nasal
cavities, paranasal sinuses and neck. Forty-two of the 62
patients received BNCT once, 17 received it twice, two
received it three times, and one received it five times.
Based on CT or MR imaging of 57 patients who had any
target lesions, 16 showed a CR, and 17 had a PR for an
overall response rate (CR+PR) of 58% at 6 months. MeST
Figure 7 Radiographic changes following BNCT in two representative patients with GBM. In both, there was a reduction in both mass and
peritumoral edema without the administration of corticosteroids or mannitol within a few days. This is also shown in the FLAIR image of Case #12.
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http://www.ro-journal.com/content/7/1/146of 53 evaluable patients was 10.1 months from time of
BNCT, and 1- and 2- year OS rates were 43% and 24%, re-
spectively. The one year survival for newly diagnosed unre-
sectable tumors was 58% and for those with recurrent
tumors it was 41%. The MeST and median progression free
survival (PFS) time and 1-year PFS rate for patients with re-
current tumors were 9.7 months, 5.1 months and 5%, re-
spectively. The best 1-year OS was seen in 6 patients with
recurrent adenocarcinomas (100%), followed by 6 with mel-
anoma (60%) and in 29 with squamous cell carcinoma
(26%). The major acute grade 3 or 4 BNCT-related toxicities
were hyperamylasemia, fatigue, mucositis/stomatitis and
pain, all of which were manageable. The most serious com-
plications were carotid artery hemorrhage in 3 patients, two
of whom died from rupture of an infected carotid artery,
which had been invaded by tumor. In summary, the overall
response rate and survival rate in both studies were compar-
able to those obtained with chemotherapy and re-irradi-
ation, but in the majority of patients this was accomplished
in one single BNCT treatment. One significant limitation of
the approach used here was that deep-seated tumors could
not receive a sufficient dose due to the limited depth of
penetration of epithermal neutrons and, therefore, BNCT
should be limited to more shallow tumors.
Study carried out in Finland
A third clinical trial, carried out in Helsinki Finland,
recently has been reported by Kankaanranta et al. [7]. A
total of 30 patients with inoperable, locally recurrent can-
cers of the head and neck region were treated with BNCT.
The majority (24 patients) had squamous cell carcinomas,
and 14 of these were staged as T4, N0. They all previously
Figure 8 Before BNCT (left) and 22 months after the first BNCT (right) of a patient with a recurrent mucoepidermoid carcinoma of the
parotid gland. Three treatments with BNCT produced a remarkable reduction in tumor size, but also resolution of a cutaneous ulcer and re-
epithelization by normal skin. These results clearly demonstrate that BNCT is a highly tumor-selective treatment modality. She lived for 7 years
following treatment (Applied Radiation and Isotopes, 61:1069–1073, 2004).
Figure 9
18FBPA-PET study prior to and 7 months following the first BNCT treatment. A. A 61 year-old female with residual maxillary
adenoid cystic carcinoma (arrows) infiltrating into pterygopalatine fossa (T4N1M0) after maxillectomy, who was treated twice with BNCT using
BPA followed by chemotherapy. B. Residual maxillary cancer and a regional lymph node metastasis were no longer evident at 42 months
although bilateral multiple pulmonary metastases were detected at 18 months after the first BNCT treatment. The patient lived for 59 months
following BNCT (Applied Radiation and Isotopes, 67:S37-S42, 2009).
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http://www.ro-journal.com/content/7/1/146had surgery and conventionally fractionated photon irradi-
ation with or without chemotherapy. Patients were evalu-
ated prior to BNCT by means of
18PET using
18F-BPA,
whenever possible, and in order to be treated by BNCT
the tumor to contralateral normal tissue ratio had to be at
least 2.5:1. Patients who were treated with BNCT received
two treatments at 3 to 5 week intervals. BPA-fructose
(400 mg/kg b.w.) was infused i.v. for 2 h prior to neutron
irradiation, which was carried out at the Finnish BNCT fa-
cility in the outskirts of Helsinki. Neutron irradiation was
performed via 2 ports; each with a median beam time of
18.6 min. Cetirizine hydrochloride was administered orally
prior to irradiation and dexamethasone (10–15 mg/d)
afterwards, in order to alleviate radiation related edema.
Figure 10 Kaplan-Meier survival plots of patients with recurrent HNC treated by Kato et al. (6) with BNCT (26 cases, red line) and those
who treated with other than BNCT (16 cases, blue line). The outcomes for the 26 patients: Mean survival time: 33.6 months, 4-year Overall
survival (OS): 37.0%, 6-year OS: 31.7%. Most of the 26 patients had either recurrent or far advanced cancers of the head and neck region and 15
(58%) had regional lymph node metastases and 6 had developed distant metastases. Nineteen of the patients had squamous cell carcinomas, 4
salivary gland carcinomas and 3 had sarcomas. All but one had received standard therapy and developed recurrent tumors for which there were
no other treatment options.
Figure 11 Kaplan-Meier survival plots of patients with either newly diagnosed or recurrent tumors of the head and neck region,
treated by Suzuki et al. with BNCT. A total of 68 patients were treated. One and 2 year OS rates were 43.1% and 24.2% respectively.
Thirty-three patients had squamous cell carcinomas (53%), 20 had adenocarcinomas (32%) and 11 (18%) had malignant melanomas.
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http://www.ro-journal.com/content/7/1/146Table 4 BNCT clinical trials using epithermal neutron beams for patients with recurrent or untreated unresectable head and neck cancer
Medical institution Neutron source Treatment
dates
Tumor type &
No. of patients
Boron compound
a Clinical outcome Ref.
Osaka University, Oral & Maxillofacial
Surgery II, Osaka, Japan
KURR (Kyoto University Research Reactor,
Osaka, Japan) or JRR-4, Japan Atomic Energy
Agency, Tokai Research Establishment,
Ibaraki, Japan
2001-2007 26 rH&N BSH 5 g & BPA 250 mg/kg in 1 h Or
BPA 250–500 mg/kg in 1–2h
MeST: 7.9 mos.
post BNCT
[5,6], This Paper
PR: 39%
CR: 46%
2 & 4 y OS: 37%,
6 y OS: 32%
Osaka Medical College, Osaka, Japan KURR 2005-2008 6 rOC BPA 500 mg/kg (200 mg/kg h×2 h;
100 mg/kg h×~1 h during
irradiation)
PR: 67% [113-115]
CR: 17%
Kyoto University Research Reactor
Institute (KURRI), Kyoto University,
Osaka, Japan
KURR 2001-2007 49 rH&N BSH & BPA 250–500 mg/kg PR: 29%, CR: 28% [116,117]
This paper
13 urH&N MeST: 10.1 mos.
(n=53)
2 y OS: 24%
Kawasaki Medical School, Kurashiki,
Japan
KURR or JRR-4 2003-2007 10 rSqCC BPA 500 mg/kg (200 mg/kg h×2 h;
100 mg/kg h×~1 h during
irradiation)
PR: 35% [4,118,119]
7 rnSqCC
3 nSqCC
CR: 55%
2 y OS: 32.3%
JRR-4 2005-2008 10 H&N MM BPA 500 mg/kg PR: 50% [120]
CR: 40%
Helsinki University Central Hospital,
Helsinki, Finland
FiR-1, VTT Technical Research Centre, Espoo,
Finland
2003-2008 24 rSqCC BPA 400 mg/kg in 2 h PR: 31% [7]
CR: 45% 6 rnSqCC
MeST: 13 mos.
post BNCT
2 y OS: 30%
2010 1 ur PDC BPA 400 mg/kg in 2 h CR: 1/1 [121]
BNCT+Chemo-RT (IMRT+SRT) with
cetuximab and cisplatin
Taipei Veterans General Hospital,
Taipei, Taiwan
THOR, National Tsing Hua University,
Hsinchu, Taiwan
2010-2011 10 rH&N BPA ~450 mg/kg (180 mg/kg h×2 h;
90 mg/kg h×~1 h during
irradiation)
PR: 40% [122,123]
CR: 30%
aThis column also indicates treatment in cases of multi-modality treatment.
Abbreviations: rH&N recurrent head and neck cancer, rOC recurrent oral cancer, ur unresectable, rSqCC recurrent squamous cell carcinoma, rnSqCC recurrent non-squamous cell carcinoma, nSCC non-squamous cell
carcinoma (naïve), H&N MM mucosal melanoma of the head and neck, PDC poorly differentiated carcinoma, XRT external beam radiation therapy (photons), IMRT intensity modulated radiation therapy, SRT stereotactic
radiation therapy, PR partial response, CR complete response, 2yO S2-year overall survival, MeST median survival time, given in months.
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6More detailed information relating to other treatments
that these patients received is provided in Kankaanranta
et al.’s recent report [7]. Twenty-nine patients were evalu-
able with a median PFS of 7.5 months, of which 22 (76%)
responded, 6 (21%) had stabilization of tumor growth for
5.1 and 20.3 months and 1 progressed. Two-year OS was
30% and PFS was 20% and 27% of the patients had no evi-
dence of recurrent disease at 2 years. Mucositis and oral
pain were the most common grade 3 adverse events, fol-
lowed by fatigue, bone necrosis in 3 patients and soft tis-
sue necrosis in one. Based on these results it was
concluded that BNCT was effective for the treatment of
inoperable locally recurrent, previously irradiated patients
with head and neck cancer. Some responses were durable,
but usually progression was common, most frequently at
the site of the previously recurrent tumor.
Study carried out in Taiwan
Finally, ten patients with recurrent, late stage cancer of the
head and neck region have been treated at the National
Tsing Hua University THOR reactor in Taiwan using BPA
as the boron delivery agent. At the time of this writing 3 of
the 10 patients have had complete regressions at the site of
treatment [122].
The clinical results described above clearly have demon-
strated efficacy, something that has been less convincingly
demonstrated in patients with high grade gliomas. This is
hardly surprising since it took a large randomized EORTC
trial [124,125] with 590 glioma patients to convincingly
demonstrate that the administration of temozolomide
concomitantly with radiation therapy produced a signifi-
cant increase in overall median survival compared to radi-
ation therapy alone and this was only 2.5 months (14.6
versus 12.1 months)!
Conclusions
What then is the future of BNCT? It probably lies in fill-
ing a niche for those malignancies, whether primary or
recurrent, for which there is no effective therapy. What
are some of the advantages of BNCT? First, it has the
ability to selectively deliver a high radiation dose to the
tumor with a much lower dose to surrounding normal
tissues. This is an important feature that makes BNCT
particularly attractive for salvage therapy of patients who
have been treated to tolerance with photon irradiation.
Second, it has the potential to more effectively target
multicentric deposits of tumor than is possible with
stereotactic radiosurgery of primary and metastatic brain
tumors. Third, although it may be only palliative, it can
produce striking clinical responses, as evidenced by the
experience of several groups treating patients with recur-
rent, therapeutically refractory head and neck cancer
[4-7,122]. Furthermore, as is evident from data compiled
in Table 2 summarizing the clinical results obtained in
treating patients with either primary or recurrent high
grade gliomas, there has been significant progress in im-
proving the clinical results. Specifically, increasing the
dose of BPA and administering it over a longer time
period (92–95) or combining BNCT with a photon boost,
as has been carried out in Japan (80), have resulted in the
best survival data obtained to date using BNCT to treat
patients with gliomas.
Critical issues that must be addressed include: 1.
Development of new low and high molecular weight boron
agents and optimization of their delivery; 2. Obtaining ap-
proval for the clinical use of these new agents from regula-
tory agencies and carrying out biodistribution studies in
patients prior to resection of their tumors; 3. Prioritizing
collaborative efforts to compare and normalize dose pre-
scriptions between centers, thus enabling studies on larger
trial populations and perhaps facilitating multi-institutional
or possibly randomized clinical trials; 4. Improvement of
methods to determine the boron dose delivered to the re-
sidual tumor volume on both macroscopic and microscopic
levels to enable more accurate tumor dose assessment. 5.
Be prepared to compete with or complement new thera-
peutic approaches. In this review we have summarized the
current status of BNCT as a treatment for high grade gli-
omas and recurrent tumors of the head and neck region
and outlined problems that we believe are important to
solve in order to move forward with BNCT as a treatment
modality. It is up to investigators, both in basic and clinical
research, to come up with solutions to these problems.
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